Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Impact of population based breast density notification: multisite parallel arm randomised controlled trial in BreastScreen.

Name: Kaimen Rigor review — Impact of population based breast density notification: multisite parallel arm randomised controlled trial in BreastScreen.
Item: Impact of population based breast density notification: multisite parallel arm randomised controlled trial in BreastScreen.
Rating: 96
Author: Alpha1

Nickel B, Ormiston-Smith N, Cvejic E, Isautier J, Hammerton L, Baker K, Legerton P, Vardon P, McInally Z, Robertson S, McCaffery K, Houssami N

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 3 high issues for “Impact of population based breast density notification: multisite parallel arm randomised controlled trial in BreastScreen.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Impact of population based breast density notification: multisite parallel arm randomised controlled trial in BreastScreen.

Nickel B, Ormiston-Smith N, Cvejic E, Isautier J, Hammerton L, Baker K, Legerton P, Vardon P, McInally Z, Robertson S, McCaffery K, Houssami N

Read full text (PMC)

DOI

10.1136/bmj-2024-083649

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/7743b7bf-e1b5-44c2-9b46-e1d9963aaa32" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/7743b7bf-e1b5-44c2-9b46-e1d9963aaa32/badge" alt="Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 3 high issues for “Impact of population based breast density notification: multisite parallel arm randomised controlled trial in BreastScreen.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

277e3275fb2237bf15f9af774d9d40c104314edc9a589c8eaded7f067e3cdfa2

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Impact of population based breast density notification: multisite parallel arm randomised controlled trial in BreastScreen.

Nickel B, Ormiston-Smith N, Cvejic E, Isautier J, Hammerton L, Baker K, Legerton P, Vardon P, McInally Z, Robertson S, McCaffery K, Houssami N

Paper source

Impact of population based breast density notification: multisite parallel arm randomised controlled trial in BreastScreen.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Findings by category

101ArithmeticNumerical inconsistencies 02OverreachNone found 103AuthenticityData authenticity concerns 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported randomized controlled trial with rigorous design, clear ethical approvals, and sound statistical analysis. The main weakness is the vague data availability statement and lack of a persistent repository for code/data, along with minor reporting gaps (statistical software not named, CONSORT not explicitly referenced).

Both reviewers classified the study as interventional (RCT) and agreed on all dimension statuses. The statistics verification recomputed 11 tests, all consistent; however, this covers only a subset of reported analyses, so the paper's statistics should not be considered fully verified. The citation check found no retracted or non-existent references.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 11 tests: 11 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 10 via agent-written checks.

Overstated conclusions

None found

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Checked — nothing surfaced.

5 major claims checked against the paper's own evidence: all adequately supported.

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

3 integrity concerns flagged (0 high).

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior research on breast density notification, including post-legislation cross-sectional studies in the US, and acknowledges the lack of robust evidence on population-level benefits versus harms. The rationale for the trial is clearly stated: to investigate the effect of notifying women of dense breasts on psychosocial outcomes and health service use intentions, and to compare written versus video information modes. Limitations of prior research are addressed by noting the lack of randomized controlled trial evidence and the need for better clarity and balance in educational materials.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with adequate citation of prior work and a logical rationale linking the premise to the study objectives.

Evidence

“Most of the evidence on the outcomes of density notification comes from post-legislation cross sectional studies in the US.”

Introduction ¶2Find in source

“The aim of this trial was to investigate the effect of notifying women participating in population based breast cancer screening that they have dense breasts on their psychosocial outcomes and intention for health services use and to determine whether using different modes of information provision (written versus video) alters these effects.”

IntroductionFind in source

“despite the lack of robust evidence on whether the benefits of notifying women at the population level outweigh the potential harms.”

Introduction ¶2Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research on breast density notification and its potential harms, and logically links this to the study's objectives.

Evidence

“Most of the evidence on the outcomes of density notification comes from post-legislation cross sectional studies in the US.”

Introduction ¶3Find in source

IntroductionFind in source

Randomization method is described (simple randomization using Oracle DBMS_RANDOM package) with equal allocation. Blinding of participants is described, though assessor blinding is not explicitly mentioned (but outcomes are self-reported, so assessor blinding is less critical). A priori sample size calculation is provided with effect size, alpha, and power. Inclusion/exclusion criteria are pre-specified. Outlier handling is addressed through complete case analysis and sensitivity analysis with multiple imputation. Controls are appropriate (standard care). Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, sample size calculation, and pre-specified inclusion/exclusion criteria.

Evidence

“we managed a simple randomisation with equal (1:1:1) allocation by using the Oracle DBMS_RANDOM package following screening results.”

MethodsFind in source

“To achieve 80% power to detect differences in proportions as small as 10% (at a Bonferroni adjusted α level of 0.017 to permit all three possible pairwise comparisons) in the primary outcomes between the control arm and each of the intervention arms, we needed a sample of 373 women randomised to each arm (total n=1119).”

MethodsFind in source

“Women were excluded if they did not have dense breasts (BI-RADS density A (almost entirely fatty) and B (scattered areas of fibroglandular density)), were recalled with screen detected abnormalities, reported a breast symptom or a clinical concern was noted by the radiographer at their screening episode, had a personal history of breast cancer, needed an interpreter (self-report on screening booking information or identified by the screening service), were unable to consent to breast screening, or did not have an active mobile phone number or email address.”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, blinding, sample size calculation, and pre-specified inclusion/exclusion criteria.

Evidence

“we managed a simple randomisation with equal (1:1:1) allocation by using the Oracle DBMS_RANDOM package following screening results.”

MethodsFind in source

Sex is reported (all female participants). Age is reported with mean and standard deviation. Demographics including education, income, language, Aboriginal and Torres Strait Islander status, and family history are reported in Table 1. Since the study includes both sexes (all female), sex_justified is not applicable. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables relevant to human participants are adequately reported, including sex, age, and demographics.

Evidence

“The mean age at baseline in the total study population was 57.4 (standard deviation 9.9).”

Results ¶1Find in source

paraphrase[Table 1]

“Highest level of education achieved: High school or below 153 (20.1) ...”

“Women aged 40 years and older who had booked mammographic screening at one of the 13 participating BreastScreen Queensland (BSQ) sites”

MethodsFind in source

PASSReviewer 2· 90% conf

Key biological variables (age, sex, breast density) and demographics are reported adequately.

Evidence

“The mean age at baseline in the total study population was 57.4 (standard deviation 9.9).”

Results ¶2Find in source

paraphrase[Table 1]

“Highest level of education achieved: High school or below 153 (20.1) ...”

The paper names the ethics committees (Gold Coast HHS Ethics Committee, Sunshine Coast, and Metro North) with protocol numbers. Informed consent is described (all participants provided informed consent). Regulatory compliance is implied through adherence to ethical standards, though not explicitly named; however, the ethics approval statement is sufficient.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval and informed consent are adequately reported.

Evidence

“Gold Coast Hospital and Health Service (HHS) Ethics Committee (HREC/2023/QGC/8977), Sunshine Coast (SSA/2023/QSC/89770), and Metro North (HREC/2023/QGC/8977) Hospital and Health Service.”

EthicsFind in source

“All participants provided informed consent to participate in the trial.”

EthicsFind in source

PASSReviewer 2· 95% conf

Ethical approval and informed consent are clearly documented.

Evidence

“Gold Coast Hospital and Health Service (HHS) Ethics Committee (HREC/2023/QGC/8977), Sunshine Coast (SSA/2023/QSC/89770), and Metro North (HREC/2023/QGC/8977) Hospital and Health Service.”

EthicsFind in source

“All participants provided informed consent to participate in the trial.”

EthicsFind in source

The investigational product (breast density notification) is described in detail, including its content and development. The software used for density measurement (Volpara Health software) and for data collection (Qualtrics) are identified. No antibodies, cell lines, or organisms are used, so those criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Key resources are adequately identified, including the investigational product (breast density notification) and software used.

Evidence

“The breast density notification (identical in both intervention 1 and intervention 2) advised women in writing in their screening results letter that no sign of breast cancer was found on their recent mammogram screen, but their screen showed that their breasts were dense (supplementary materials).”

MethodsFind in source

“automated volumetric density measures using Volpara Health software”

MethodsFind in source

“collected via the online questionnaire (supplementary materrials) using Qualtrics”

MethodsFind in source

PASSReviewer 2· 85% conf

The investigational product (breast density notification) is described, and software used for analysis is identified.

Evidence

“automated volumetric density measures using Volpara Health software”

MethodsFind in source

“collected via the online questionnaire (supplementary materrials) using Qualtrics”

MethodsFind in source

Statistical tests are named (ordinal and multinomial logistic regression). Assumptions are verified (Brant-Wald test for proportional odds). Exact p-values are reported. Effect sizes with confidence intervals are reported. Statistical software is not explicitly identified, but the analysis methods are described. Data presentation includes per-group n and percentages. Mathematical plausibility checks were not performed due to lack of raw data, but no obvious inconsistencies were found.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical analysis is rigorous with named tests, exact p-values, effect sizes with confidence intervals, and appropriate data presentation.

Evidence

“We used generalised linear models (ordinal or multinomial logistic regression, as appropriate, presented as odds ratios or relative risk ratios, respectively) to analyse outcome data across study arms as complete case analyses.”

Statistical analysisFind in source

“We assessed the proportional odds assumption for ordinal logistic regression by using a Brant-Wald test.”

Statistical analysisFind in source

paraphrase[Results, paragraph 2]

“intervention 1: odds ratio 1.30, 95% confidence interval (CI) 1.08 to 1.57 (P=0.005)”

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

Statistical analysisFind in source

paraphrase[Results, paragraph 3]

“intervention 1: odds ratio 1.30, 95% confidence interval (CI) 1.08 to 1.57 (P=0.005)”

The data availability statement says 'The code used to analyse the data in the paper can be found in the supplementary materials.' This is vague and does not provide a clear route for data access. No repository deposit or accession numbers are provided. Code is shared in supplementary materials, which is not a version-controlled public repository.

Sub-criteria

code sharingINADEQUATE

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

Data availability statement is present but vague; code is available in supplementary materials but not in a public repository.

Evidence

“The code used to analyse the data in the paper can be found in the supplementary materials.”

Data availabilityFind in source

absence[Data availability statement]

No repository deposit is mentioned.

WARNReviewer 2· 80% conf

Data availability statement is vague, and code is only in supplementary materials without a persistent identifier.

Evidence

“The code used to analyse the data in the paper can be found in the supplementary materials.”

Data availabilityFind in source

The trial is registered (ACTRN12623000001695). Funding sources and competing interests are declared. Limitations are discussed in detail. Conclusions are proportional to the evidence. Methods are described in sufficient detail for replication. Reporting guideline (CONSORT) is implied through the flow diagram, though not explicitly referenced.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, funding/COI statements, and limitations discussed.

Evidence

“Trial registration Australian New Zealand Clinical Trials Registry (ACTRN12623000001695).”

AbstractFind in source

“Funding: This work was supported by a National Health and Medical Research Council (NHMRC) Emerging Leader Research Fellowship (1194108) to BN and a National Breast Cancer Foundation chair in breast cancer prevention grant (EC-21-001) to NH.”

FundingFind in source

“The new findings from this trial should be interpreted in the context of its limitations.”

LimitationsFind in source

PASSReviewer 2· 90% conf

The paper is transparent with trial registration, limitations, and funding/COI statements.

Evidence

“Trial registration Australian New Zealand Clinical Trials Registry (ACTRN12623000001695).”

AbstractFind in source

“Although all women received the same density notification integrated in the mammogram results letter, a limitation is the low proportion of women in the video intervention arm who viewed the additional information.”

LimitationsFind in source

Registered (1 ID: ANZCTR). Reporting guideline cited: CONSORT.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 48 references by DOI: 42 verified — 6 no DOI (shown, not verified).

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published paper is methodologically robust and its conclusions are supported by the reported analyses. An informed reader should weigh the minor reporting gaps (data availability, statistical software, CONSORT reference) and the fact that only a subset of statistics were independently recomputed; none of these undermine the core findings, but a correction or clarification of the data availability statement would improve reproducibility.

1.
HIGHdata code
In the Data availability statement, specify a concrete access route for the de-identified dataset (e.g., a data access committee with contact details and conditions) and provide a persistent identifier (DOI) for the analysis code in a public repository such as Zenodo or GitHub.
The current statement only mentions code in supplementary materials, which is inadequate for reproducibility and does not meet common journal requirements for clinical trials.
2.
HIGHreporting
In the Methods or a dedicated section, explicitly state adherence to the CONSORT reporting guideline and provide a completed CONSORT checklist as a supplementary file.
The flow diagram implies CONSORT but the guideline is not referenced, which is a reporting transparency gap that reviewers may flag.
3.
HIGHstatistics
In the Statistical analysis section, name the statistical software and version used (e.g., R version 4.3.1, Stata 18) for all analyses.
Both reviewers noted that statistical software is not identified, which hampers reproducibility.
4.
MEDIUMethics
In the Ethics statements, add an explicit statement of compliance with the Declaration of Helsinki or equivalent regulatory standards.
Reviewer 2 flagged regulatory compliance as not explicitly stated; adding this clarifies ethical oversight.
5.
MEDIUMrigor
In the Methods, clarify whether outcome assessors were blinded to group allocation, even though outcomes are self-reported.
Blinding of assessors is not explicitly described; clarifying this addresses a potential source of bias.
6.
MEDIUMrigor
In the Results or Discussion, report the number of women in intervention 1 who accessed the written information, and in intervention 2 who partially viewed the video, to aid interpretation of engagement.
The paper reports only full video views; partial access data would help interpret the intervention's reach.
7.
MEDIUMreporting
In the Methods, provide more detail on the development and validation of the study-specific questionnaire measures used as outcomes.
Reviewer 2 suggested this; it would strengthen the validity of the outcome measures.
8.
LOWcopyedit
Fix the typo 'supplementary materrials' to 'supplementary materials' in Methods, Outcomes.
Typographical error that should be corrected.
9.
LOWcopyedit
Standardize p-value formatting to 'P<0.001' throughout the Results (currently 'P<.001' appears in paragraphs 2 and 3).
Inconsistent formatting of p-values is a minor copyedit issue.
10.
LOWcopyedit
In the Discussion, replace 'supplementary ultrasonography or MRI' with 'supplemental ultrasonography or MRI' for consistency.
Inconsistent use of 'supplementary' vs 'supplemental'.
11.
LOWcopyedit
In the Discussion, Strengths and limitations, rephrase the sentence about participation rates for clarity: 'Although only a third of invited women consented, participation rates in cancer screening trials vary widely, and opt-in consent typically leads to lower participation.'
The original phrasing is slightly awkward and could be clearer.
12.
LOWcopyedit
In the Discussion, Policy and practice implications, fix the typo 'screenng' to 'screening'.
Typographical error.

Full text (51,202 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Impact of population based breast density notification: multisite parallel arm randomised controlled trial in BreastScreen.

Nickel B, Ormiston-Smith N, Cvejic E, Isautier J, Hammerton L, Baker K, Legerton P, Vardon P, McInally Z, Robertson S, McCaffery K, Houssami N

Read full text (PMC)

DOI

10.1136/bmj-2024-083649

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/7743b7bf-e1b5-44c2-9b46-e1d9963aaa32" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/7743b7bf-e1b5-44c2-9b46-e1d9963aaa32/badge" alt="Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 3 high issues for “Impact of population based breast density notification: multisite parallel arm randomised controlled trial in BreastScreen.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

277e3275fb2237bf15f9af774d9d40c104314edc9a589c8eaded7f067e3cdfa2

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Findings by category

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 11 tests: 11 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 10 via agent-written checks.

Overstated conclusions

None found

Checked — nothing surfaced.

5 major claims checked against the paper's own evidence: all adequately supported.

Data authenticity concerns

1 finding · worst low

Other integrity concernAssessed

3 integrity concerns flagged (0 high).

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with adequate citation of prior work and a logical rationale linking the premise to the study objectives.

Evidence

“Most of the evidence on the outcomes of density notification comes from post-legislation cross sectional studies in the US.”

Introduction ¶2Find in source

IntroductionFind in source

“despite the lack of robust evidence on whether the benefits of notifying women at the population level outweigh the potential harms.”

Introduction ¶2Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research on breast density notification and its potential harms, and logically links this to the study's objectives.

Evidence

“Most of the evidence on the outcomes of density notification comes from post-legislation cross sectional studies in the US.”

Introduction ¶3Find in source

IntroductionFind in source

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, sample size calculation, and pre-specified inclusion/exclusion criteria.

Evidence

“we managed a simple randomisation with equal (1:1:1) allocation by using the Oracle DBMS_RANDOM package following screening results.”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, blinding, sample size calculation, and pre-specified inclusion/exclusion criteria.

Evidence

“we managed a simple randomisation with equal (1:1:1) allocation by using the Oracle DBMS_RANDOM package following screening results.”

MethodsFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables relevant to human participants are adequately reported, including sex, age, and demographics.

Evidence

“The mean age at baseline in the total study population was 57.4 (standard deviation 9.9).”

Results ¶1Find in source

paraphrase[Table 1]

“Highest level of education achieved: High school or below 153 (20.1) ...”

“Women aged 40 years and older who had booked mammographic screening at one of the 13 participating BreastScreen Queensland (BSQ) sites”

MethodsFind in source

PASSReviewer 2· 90% conf

Key biological variables (age, sex, breast density) and demographics are reported adequately.

Evidence

“The mean age at baseline in the total study population was 57.4 (standard deviation 9.9).”

Results ¶2Find in source

paraphrase[Table 1]

“Highest level of education achieved: High school or below 153 (20.1) ...”

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval and informed consent are adequately reported.

Evidence

“Gold Coast Hospital and Health Service (HHS) Ethics Committee (HREC/2023/QGC/8977), Sunshine Coast (SSA/2023/QSC/89770), and Metro North (HREC/2023/QGC/8977) Hospital and Health Service.”

EthicsFind in source

“All participants provided informed consent to participate in the trial.”

EthicsFind in source

PASSReviewer 2· 95% conf

Ethical approval and informed consent are clearly documented.

Evidence

“Gold Coast Hospital and Health Service (HHS) Ethics Committee (HREC/2023/QGC/8977), Sunshine Coast (SSA/2023/QSC/89770), and Metro North (HREC/2023/QGC/8977) Hospital and Health Service.”

EthicsFind in source

“All participants provided informed consent to participate in the trial.”

EthicsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Key resources are adequately identified, including the investigational product (breast density notification) and software used.

Evidence

MethodsFind in source

“automated volumetric density measures using Volpara Health software”

MethodsFind in source

“collected via the online questionnaire (supplementary materrials) using Qualtrics”

MethodsFind in source

PASSReviewer 2· 85% conf

The investigational product (breast density notification) is described, and software used for analysis is identified.

Evidence

“automated volumetric density measures using Volpara Health software”

MethodsFind in source

“collected via the online questionnaire (supplementary materrials) using Qualtrics”

MethodsFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical analysis is rigorous with named tests, exact p-values, effect sizes with confidence intervals, and appropriate data presentation.

Evidence

Statistical analysisFind in source

“We assessed the proportional odds assumption for ordinal logistic regression by using a Brant-Wald test.”

Statistical analysisFind in source

paraphrase[Results, paragraph 2]

“intervention 1: odds ratio 1.30, 95% confidence interval (CI) 1.08 to 1.57 (P=0.005)”

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

Statistical analysisFind in source

paraphrase[Results, paragraph 3]

“intervention 1: odds ratio 1.30, 95% confidence interval (CI) 1.08 to 1.57 (P=0.005)”

Sub-criteria

code sharingINADEQUATE

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

Data availability statement is present but vague; code is available in supplementary materials but not in a public repository.

Evidence

“The code used to analyse the data in the paper can be found in the supplementary materials.”

Data availabilityFind in source

absence[Data availability statement]

No repository deposit is mentioned.

WARNReviewer 2· 80% conf

Data availability statement is vague, and code is only in supplementary materials without a persistent identifier.

Evidence

“The code used to analyse the data in the paper can be found in the supplementary materials.”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, funding/COI statements, and limitations discussed.

Evidence

“Trial registration Australian New Zealand Clinical Trials Registry (ACTRN12623000001695).”

AbstractFind in source

FundingFind in source

“The new findings from this trial should be interpreted in the context of its limitations.”

LimitationsFind in source

PASSReviewer 2· 90% conf

The paper is transparent with trial registration, limitations, and funding/COI statements.

Evidence

“Trial registration Australian New Zealand Clinical Trials Registry (ACTRN12623000001695).”

AbstractFind in source

LimitationsFind in source

Registered (1 ID: ANZCTR). Reporting guideline cited: CONSORT.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 48 references by DOI: 42 verified — 6 no DOI (shown, not verified).

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHdata code
In the Data availability statement, specify a concrete access route for the de-identified dataset (e.g., a data access committee with contact details and conditions) and provide a persistent identifier (DOI) for the analysis code in a public repository such as Zenodo or GitHub.
The current statement only mentions code in supplementary materials, which is inadequate for reproducibility and does not meet common journal requirements for clinical trials.
2.
HIGHreporting
In the Methods or a dedicated section, explicitly state adherence to the CONSORT reporting guideline and provide a completed CONSORT checklist as a supplementary file.
The flow diagram implies CONSORT but the guideline is not referenced, which is a reporting transparency gap that reviewers may flag.
3.
HIGHstatistics
In the Statistical analysis section, name the statistical software and version used (e.g., R version 4.3.1, Stata 18) for all analyses.
Both reviewers noted that statistical software is not identified, which hampers reproducibility.
4.
MEDIUMethics
In the Ethics statements, add an explicit statement of compliance with the Declaration of Helsinki or equivalent regulatory standards.
Reviewer 2 flagged regulatory compliance as not explicitly stated; adding this clarifies ethical oversight.
5.
MEDIUMrigor
In the Methods, clarify whether outcome assessors were blinded to group allocation, even though outcomes are self-reported.
Blinding of assessors is not explicitly described; clarifying this addresses a potential source of bias.
6.
MEDIUMrigor
In the Results or Discussion, report the number of women in intervention 1 who accessed the written information, and in intervention 2 who partially viewed the video, to aid interpretation of engagement.
The paper reports only full video views; partial access data would help interpret the intervention's reach.
7.
MEDIUMreporting
In the Methods, provide more detail on the development and validation of the study-specific questionnaire measures used as outcomes.
Reviewer 2 suggested this; it would strengthen the validity of the outcome measures.
8.
LOWcopyedit
Fix the typo 'supplementary materrials' to 'supplementary materials' in Methods, Outcomes.
Typographical error that should be corrected.
9.
LOWcopyedit
Standardize p-value formatting to 'P<0.001' throughout the Results (currently 'P<.001' appears in paragraphs 2 and 3).
Inconsistent formatting of p-values is a minor copyedit issue.
10.
LOWcopyedit
In the Discussion, replace 'supplementary ultrasonography or MRI' with 'supplemental ultrasonography or MRI' for consistency.
Inconsistent use of 'supplementary' vs 'supplemental'.
11.
LOWcopyedit
In the Discussion, Strengths and limitations, rephrase the sentence about participation rates for clarity: 'Although only a third of invited women consented, participation rates in cancer screening trials vary widely, and opt-in consent typically leads to lower participation.'
The original phrasing is slightly awkward and could be clearer.
12.
LOWcopyedit
In the Discussion, Policy and practice implications, fix the typo 'screenng' to 'screening'.
Typographical error.

Full text (51,202 chars)Analyzed: Aug 15, 2026